Additionally, there are a great deal of other ongoing trials exploring ribociclib in combination with other targeted agents for BC, such as the PACE trial (NCT03147287) and MAINTAIN trial (NCT02632045), which are being carried out to evaluate the efficacy of Ribociclib in HR+ MBC patients previously treated with a CDK4/6 inhibitor. This evidence concerns the gene CDK4 and breast cancer.